Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Celecoxib Oral Solution Treats Migraine in Randomized Trial

Key clinical point: An oral liquid solution of celecoxib, known as DFN-15, is more effective than placebo for the acute treatment of migraine.

Major finding: At 2 hours, pain freedom rates were 35.6% with celecoxib oral solution and 21.7% with placebo. The rates of freedom from the most bothersome symptom were 57.8% with celecoxib oral solution and 44.8% with placebo.

Study details: A randomized, double-blind, placebo-controlled study that included about 600 patients with episodic migraine with or without aura.

Disclosures: The trial was supported by Dr. Reddy’s Laboratories, manufacturer of DFN-15. Two authors are employed by and own stock in Dr. Reddy’s. Other authors disclosed research support from and consulting for Dr. Reddy’s and other companies.

Citation:

Lipton RB et al. Headache. 2020;60(1):58-70. doi: 10.1111/head.13663.